VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Upfront Treatment Strategies for Metastatic Colorectal Cancer

Panelists:Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada; Richard M. Goldberg, MD, Ohio State University Comprehensive Cancer Center; Howard S. Hochster, MD, Yale Cancer Center; John L. Marshall, MD, Georgetown University Hospital
Published: Tuesday, Sep 22, 2015

 
Resection is ideal for eligible patients with colorectal cancer (CRC), since it is easier to eradicate micrometastatic disease with systemic therapies, according to Richard L. Goldberg, MD. Upfront chemotherapy may be appropriate, if the disease is borderline resectable or if downstaging could potentially change the surgical outcome, adds Howard S. Hochster, MD.

In a patient who has a rectal tumor close to the anal verge and one isolated 2-cm liver lesion, upfront systemic therapy may be appropriate, says Fadi Braiteh, MD. After completing induction therapy, it is best to remove microscopic disease first, adds Braiteh. In this setting, chemoradiation and standard management of the rectal primary tumor could delay liver treatment and lead to further disease progression, notes Braiteh.

An individual with low levels of carcinoembryonic antigen (CEA), one positive node, a single small lesion, and synchronous disease post surgery would have one point on the Fong score, translating to a 50% probability of cure with no further therapy, says Goldberg. The benefit of adding adjuvant therapy in this setting is unclear, but it may improve the chances of cure, adds Goldberg, who prefers to use cytotoxic therapies as adjuvant treatment.

Discontinuing chemotherapy depends on the bulk of the disease, the pace of disease, and patient-specific goals, says Goldberg. Many patients will need a break before restarting treatment, adds Hochster.
 
Slider Left
Slider Right

 
Resection is ideal for eligible patients with colorectal cancer (CRC), since it is easier to eradicate micrometastatic disease with systemic therapies, according to Richard L. Goldberg, MD. Upfront chemotherapy may be appropriate, if the disease is borderline resectable or if downstaging could potentially change the surgical outcome, adds Howard S. Hochster, MD.

In a patient who has a rectal tumor close to the anal verge and one isolated 2-cm liver lesion, upfront systemic therapy may be appropriate, says Fadi Braiteh, MD. After completing induction therapy, it is best to remove microscopic disease first, adds Braiteh. In this setting, chemoradiation and standard management of the rectal primary tumor could delay liver treatment and lead to further disease progression, notes Braiteh.

An individual with low levels of carcinoembryonic antigen (CEA), one positive node, a single small lesion, and synchronous disease post surgery would have one point on the Fong score, translating to a 50% probability of cure with no further therapy, says Goldberg. The benefit of adding adjuvant therapy in this setting is unclear, but it may improve the chances of cure, adds Goldberg, who prefers to use cytotoxic therapies as adjuvant treatment.

Discontinuing chemotherapy depends on the bulk of the disease, the pace of disease, and patient-specific goals, says Goldberg. Many patients will need a break before restarting treatment, adds Hochster.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x